ADCT vs OABI
ADCT: ADC Therapeutics develops antibody-drug conjugates (ADCs) targeting hematologic and solid tumors, with its lead product ZYNLONTA commercialized for lymphoma. OABI: OmniAb provides a proprietary, AI-enhanced transgenic animal platform that accelerates the discovery of human antibody therapeutics for global pharmaceutical and biotech partners.
Side-by-side fundamentals
| Metric | ADCT | OABI | Edge |
|---|---|---|---|
| Price as of 2026-07-30 close | $1.11 | $2.03 | |
| Market cap as of 2026-07-31 | $141M | $294M | |
| Net margin as of 2026-07-31 | -173.0% | -187.6% | ADCT higher |
| Gross margin as of 2026-07-31 | +90.7% | +98.9% | OABI higher |
| Operating margin as of 2026-07-31 | -149.4% | -200.3% | ADCT higher |
| ROE as of 2026-07-31 | -229.2% | -20.3% | OABI higher |
| ROA as of 2026-07-31 | -44.7% | -18.1% | OABI higher |
| Debt / equity as of 2026-07-31 | 9.01 | 0.00 | OABI lower |
| Revenue growth (YoY) as of 2026-07-31 | +4.4% | +8.2% | OABI higher |
| Revenue CAGR (3y) SEC XBRL | -27.1% | -31.9% | ADCT higher |
| Dividend streak (yrs) SEC XBRL | n/a | 1 | |
| Beta as of 2026-07-31 | 1.46 | 0.48 | |
| 1-year return as of 2026-07-30 close | -62.2% | -3.3% | OABI higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.